Lung Cancer Resistance to Gefitinib
Author Information
Author(s): Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Shibuya M, Kudoh S
Primary Institution: Nippon Medical School
Hypothesis
What are the mechanisms behind natural resistance to gefitinib in lung cancer?
Conclusion
The study found that loss of PTEN protein and the absence of EGFR gene mutation are associated with natural resistance to gefitinib in lung cancer cell lines.
Supporting Evidence
- Gefitinib-resistant cell lines showed increased Akt phosphorylation and reduced PTEN expression.
- Loss of the EGFR gene mutation was observed in gefitinib-resistant subpopulations.
- Reintroduction of PTEN may be a potential strategy to overcome gefitinib resistance.
Takeaway
Some lung cancer cells can resist a drug called gefitinib because they lose a protein called PTEN, which helps control cell growth.
Methodology
The study analyzed NSCLC cell lines for gefitinib sensitivity using the MTT assay and examined gene expression profiles and signaling pathways.
Limitations
The study primarily used cell lines, which may not fully represent the complexity of human tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website